Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNXU NASDAQ:NNOX NASDAQ:SGHT NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNXUConexeu Sciences$8.55-0.2%$11.71$8.14▼$18.79$228.78MN/A99,802 shs7,291 shsNNOXNano-X Imaging$0.94+5.4%$1.50$0.73▼$5.26$65.71M1.241.63 million shs135,725 shsSGHTSight Sciences$4.99+1.6%$5.07$3.11▼$9.24$271.51M2.38267,760 shs650 shsTMCITreace Medical Concepts$4.07+1.8%$3.88$1.17▼$7.78$264.02M1.37784,705 shs3,679 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNXUConexeu Sciences0.00%-12.82%-21.81%+856,999,900.00%+856,999,900.00%NNOXNano-X Imaging0.00%-19.98%-17.78%-51.82%-82.77%SGHTSight Sciences0.00%-2.39%-13.71%+13.66%+40.69%TMCITreace Medical Concepts0.00%-6.98%-10.31%+108.33%-29.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNXUConexeu Sciences$8.55-0.2%$11.71$8.14▼$18.79$228.78MN/A99,802 shs7,291 shsNNOXNano-X Imaging$0.94+5.4%$1.50$0.73▼$5.26$65.71M1.241.63 million shs135,725 shsSGHTSight Sciences$4.99+1.6%$5.07$3.11▼$9.24$271.51M2.38267,760 shs650 shsTMCITreace Medical Concepts$4.07+1.8%$3.88$1.17▼$7.78$264.02M1.37784,705 shs3,679 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNXUConexeu Sciences0.00%-12.82%-21.81%+856,999,900.00%+856,999,900.00%NNOXNano-X Imaging0.00%-19.98%-17.78%-51.82%-82.77%SGHTSight Sciences0.00%-2.39%-13.71%+13.66%+40.69%TMCITreace Medical Concepts0.00%-6.98%-10.31%+108.33%-29.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNXUConexeu Sciences 2.50Moderate Buy$20.00133.92% UpsideNNOXNano-X Imaging 2.67Moderate Buy$4.00323.64% UpsideSGHTSight Sciences 2.44Hold$8.2565.33% UpsideTMCITreace Medical Concepts 1.86Reduce$4.9722.11% UpsideCurrent Analyst Ratings BreakdownLatest NNOX, SGHT, TMCI, and CNXU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026TMCITreace Medical Concepts Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$2.00 ➝ $4.007/8/2026NNOXNano-X Imaging Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/8/2026SGHTSight Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$5.15 ➝ $6.007/7/2026NNOXNano-X Imaging Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.00 ➝ $3.006/29/2026CNXUConexeu Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/22/2026CNXUConexeu Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/22/2026NNOXNano-X Imaging Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/15/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026SGHTSight Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$4.35 ➝ $5.155/11/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNXUConexeu SciencesN/AN/AN/AN/AN/AN/ANNOXNano-X Imaging$13.02M5.05N/AN/A$2.01 per share0.47SGHTSight Sciences$77.36M3.51N/AN/A$1.21 per share4.12TMCITreace Medical Concepts$212.69M1.24N/AN/A$1.37 per share2.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNXUConexeu SciencesN/A-$0.11N/AN/AN/AN/AN/AN/AN/ANNOXNano-X Imaging-$75.02M-$1.58N/AN/AN/A-716.44%-70.96%-62.26%8/11/2026 (Estimated)SGHTSight Sciences-$38.43M-$0.71N/AN/AN/A-46.83%-52.34%-28.49%8/5/2026 (Estimated)TMCITreace Medical Concepts-$59M-$0.97N/AN/AN/A-29.44%-67.04%-30.28%8/7/2026 (Estimated)Latest NNOX, SGHT, TMCI, and CNXU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026N/ANNOXNano-X Imaging-$0.1633N/AN/AN/A$5.39 millionN/A8/7/2026Q2 2026TMCITreace Medical Concepts-$0.30N/AN/AN/A$44.02 millionN/A8/5/2026Q2 2026SGHTSight Sciences-$0.15N/AN/AN/A$21.69 millionN/A6/25/2026Q1 2026NNOXNano-X ImagingN/A-$0.16N/A-$0.20N/A$4.31 million6/15/2026Q2 2026CNXUConexeu SciencesN/A-$0.11N/A-$0.11N/AN/A5/8/2026Q1 2026TMCITreace Medical Concepts-$0.31-$0.28+$0.03-$0.28$45.96 million$47.20 million5/6/2026Q1 2026SGHTSight Sciences-$0.19-$0.24-$0.05-$0.24$18.47 million$19.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNXUConexeu SciencesN/AN/AN/AN/AN/ANNOXNano-X ImagingN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNXUConexeu SciencesN/AN/AN/ANNOXNano-X ImagingN/A3.643.40SGHTSight Sciences0.685.865.48TMCITreace Medical Concepts0.723.582.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNXUConexeu SciencesN/ANNOXNano-X Imaging21.49%SGHTSight Sciences55.51%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipCNXUConexeu SciencesN/ANNOXNano-X ImagingN/ASGHTSight Sciences30.40%TMCITreace Medical Concepts23.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNXUConexeu Sciences426.76 millionN/AN/ANNOXNano-X Imaging19069.59 millionN/AOptionableSGHTSight Sciences21054.41 million37.87 millionOptionableTMCITreace Medical Concepts25064.87 million49.68 millionOptionableNNOX, SGHT, TMCI, and CNXU HeadlinesRecent News About These CompaniesDid Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?July 24 at 2:24 PM | prnewswire.comTreace to Report Second Quarter 2026 Financial Results on August 7, 2026July 24 at 7:05 AM | globenewswire.comWhy Treace Medical Concepts, Inc.’s (TMCI) Stock Is Down 5.42%July 23, 2026 | aaii.comAAnalyzing Atossa Genetics (NASDAQ:ATOS) and Treace Medical Concepts (NASDAQ:TMCI)July 23, 2026 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from AnalystsJuly 22, 2026 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) Stock Price Expected to Rise, Truist Financial Analyst SaysJuly 18, 2026 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from BrokeragesJuly 17, 2026 | marketbeat.comTreace Medical Concepts (NASDAQ:TMCI) Given New $4.00 Price Target at Truist FinancialJuly 16, 2026 | marketbeat.comFinancial Comparison: Treace Medical Concepts (NASDAQ:TMCI) versus Tactile Systems Technology (NASDAQ:TCMD)July 16, 2026 | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Short Interest Down 46.6% in JuneJuly 15, 2026 | marketbeat.comJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)July 13, 2026 | globenewswire.comTMCI Share News TodayJune 30, 2026 | uk.investing.comTreace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant SystemJune 18, 2026 | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 22,887 SharesJune 12, 2026 | insidertrades.comTreace to Present at the Sidoti Small Cap ConferenceJune 11, 2026 | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 50,000 SharesJune 2, 2026 | insidertrades.comTreace Medical Concepts Balances Growth With Earnings StrainJune 1, 2026 | tipranks.comJohn Treace Purchases 4,508 Shares of Treace Medical Concepts (NASDAQ:TMCI) StockMay 29, 2026 | insidertrades.comTreace Medical Shareholders Back Directors, Pay and AuditorMay 20, 2026 | tipranks.comTreace Medical Concepts, Inc.May 15, 2026 | edition.cnn.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 43,000 SharesMay 15, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNNOX, SGHT, TMCI, and CNXU Company DescriptionsConexeu Sciences NASDAQ:CNXU$8.55 -0.02 (-0.23%) As of 09:34 AM EasternConexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.Nano-X Imaging NASDAQ:NNOX$0.94 +0.05 (+5.36%) As of 09:40 AM EasternNano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.Sight Sciences NASDAQ:SGHT$4.99 +0.08 (+1.63%) As of 09:34 AM EasternSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Treace Medical Concepts NASDAQ:TMCI$4.07 +0.07 (+1.75%) As of 09:35 AM EasternTreace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware This Tiny AI Supplier Could Be More Important Than the Chipmakers Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Meta Earnings Put AI Spending and Ad Growth Back in Focus These 3 AI Winners Don’t Sell the Tech—They Use It Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
